23600 Federal Register / Vol. 76, No. 81 / Wednesday, April 27, 2011 / Notices 

Guidelines to Agencies on 

Governmentwide Debarment and 

Suspension (2 CFR 376 et seq.); and 

(2) Dr. Bhrigu is prohibited from 

serving in any advisory capacity to the 

U.S. Public Health Service (PHS), 

including but not limited to service on 

any PHS advisory committee, board, 

and/or peer review committee, or as a 

consultant. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8800. 

John Dahlberg, 

Director, Division of Investigative Oversight, 

Office of Research Integrity. 

[FR Doc. 2011–10150 Filed 4–26–11; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Office of the Secretary 

Findings of Research Misconduct 

AGENCY: Office of the Secretary, HHS. 

ACTION: Notice. 

SUMMARY: Notice is hereby given that 

the Office of Research Integrity (ORI) 

has taken final action in the following 

case: 

Junghee J. Shin, PhD, New York 

Medical College: Based on the report of 

an investigation conducted by New 

York Medical College (NYMC) and 

additional analysis by the Office of 

Research Integrity (ORI) in its oversight 

review, the U.S. Public Health Service 

(PHS) found that Junghee J. Shin, PhD, 

former graduate student, NYMC, 

engaged in research misconduct in 

research supported by National Institute 

of Allergy and Infectious Diseases 

(NIAID), National Institutes of Health 

(NIH), grants R01 AI048856 and R01 

AI043063. 

PHS found that the Respondent 

engaged in research misconduct by 

falsifying data in Figure 4 of a 

manuscript submitted to the journal 

Infection and Immunity (Shin, J.J., 

Godfrey, H.P., & Cabello, F.C. 

‘‘Expression and localization of BmpC in 

Borrelia burgdorferi after growth under 

various environmental conditions.’’ 

Submitted to Infection and Immunity; 

hereafter referred to as the 

‘‘manuscript’’) and Figure 5 of a paper 

published in Infection and Immunity 

(Shin, J.J. Bryksin, A.V., Godfrey, H.P., 

& Cabello, F.C. ‘‘Localization of BmpA 

on the exposed outer membrane of 

Borrelia burgdorferi by monospecific 

anti-recombinant BmpA rabbit 

antibodies.’’ Infection and Immunity 

72(4):2280–2287, April 2004; hereafter 

referred to as the ‘‘paper.’’ Retracted in: 

Infection and Immunity 76(10):4792, 

October 2008). Specifically, NYMC and 

ORI found that: 

• Dr. Shin falsified microscopic 

immunofluorescence blank images in 

Figure 4 of the manuscript (top row, 1st, 

2nd, 4th, and 5th panels, and bottom 

row, 1st panel) and Figure 5 of the paper 

(top row, 1st and 5th panels, lower 1st 

panel) by using one blank image from an 

unknown experiment to falsely 

represent the preimmunization control 

conditions (intact cells and methanol 

fixation) as well as the negative staining 

of anti-BmpC and anti-FlaB in Figure 4 

and anti-FlaB in Figure 5 on intact cells. 

• Dr. Shin falsified at least one of two 

images in Figure 4 of the manuscript 

and Figure 5 of the paper by using 

different portions of a green-red pair of 

microscopic immunofluorescence 

images (1230036.tif and 1230037.tif) 

because unfixed cells staining positive 

for BmpA in the top row, 4th panel, of 

Figure 5 were the same unfixed cells 

purportedly positive for OspA in the top 

row, 3rd panel, of Figure 4. 

• Dr. Shin falsified at least one of two 

images in Figure 4 of the manuscript 

and Figure 5 of the paper by using 

different photo cropping from a single 

microscopic immunofluorescence image 

(1230039.tif) to represent fixed cells 

positive for BmpA and labeled with 

anti-FlaB in the lower row, 5th panel, of 

Figure 5 and to also represent fixed cells 

positive for BmpC and stained with 

anti-FlaB in the lower row, 5th panel, of 

Figure 4. 

Dr. Shin has entered into a Voluntary 

Settlement Agreement in which she has 

voluntarily agreed, for a period of three 

(3) years, beginning on April 5, 2011: 

(1) That any institution that submits 

an application for PHS support for a 

research project on which the 

Respondent’s participation is proposed 

or that uses her in any capacity on PHSsupported research, or that submits a 

report of PHS-funded research in which 

she is involved, must concurrently 

submit a plan for supervision of her 

duties to ORI for approval; the 

supervisory plan must be designed to 

ensure the scientific integrity of her 

research contribution; Respondent 

agrees that she will not participate in 

any PHS-supported research until such 

a supervision plan is submitted to ORI; 

and 

(2) to exclude herself voluntarily from 

service in any advisory capacity to PHS, 

including but not limited to service on 

any PHS advisory committee, board, 

and/or peer review committee, or as a 

consultant. 

FOR FURTHER INFORMATION CONTACT: 

Director, Division of Investigative 

Oversight, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8800. 

John Dahlberg, 

Director, Division of Investigative Oversight, 

Office of Research Integrity. 

[FR Doc. 2011–10157 Filed 4–26–11; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Agency for Toxic Substances and 

Disease Registry 

[CDC–2011–0005] 

Availability of Draft Toxicological 

Profile 

AGENCY: Agency for Toxic Substances 

and Disease Registry (ATSDR), 

Department of Health and Human 

Services (DHHS). 

ACTION: Notice of availability. 

SUMMARY: This notice announces the 

availability of the Toxicological Profile 

for Uranium (Update) for review and 

comment. These comments can include 

additional information or reports on 

studies about the health effects of 

uranium. Although ATSDR considered 

key studies for uranium during the 

profile development process, this 

Federal Register notice solicits any 

relevant, additional studies, particularly 

unpublished data. ATSDR will evaluate 

the quality and relevance of such data 

or studies for possible addition to the 

profile. ATSDR remains committed to 

providing a public comment period for 

this document as a means to best serve 

public health and our clients. 

The Comprehensive Environmental 

Response, Compensation, and Liability 

Act of 1980 (CERCLA), as amended by 

the Superfund Amendments and 

Reauthorization Act of 1986 (SARA), 

§ 104(i)(3), [42 U.S.C. 9604(i)(3)], directs 

the ATSDR administrator to prepare 

toxicological profiles of priority 

hazardous substances and, as necessary, 

to revise and publish each updated 

toxicological profile. 

DATES: To be considered, comments on 

this draft toxicological profile must be 

received not later than July 29th, 2011. 

Comments received after the close of the 

public comment period will be 

considered at the discretion of ATSDR, 

based upon what is deemed to be in the 

best interest of the general public. 

ADDRESSES: Requests for printed copies 

of the draft toxicological profile should 

be sent via e-mail to cdcinfo@cdc.gov, or 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES

Federal Register / Vol. 76, No. 81 / Wednesday, April 27, 2011 / Notices 23601 

to Ms. Delores Grant, Division of 

Toxicology and Environmental 

Medicine, Agency for Toxic Substances 

and Disease Registry, Mailstop F–62, 

1600 Clifton Road, NE., Atlanta, Georgia 

30333. Electronic access to this 

document is also available at the 

ATSDR Web site: http:// 

www.atsdr.cdc.gov/toxprofiles/ 

index.asp. 

Electronic comments may be sent via 

http://www.regulations.gov, docket 

control number CDC–2011–0005. Please 

follow the directions on the site to 

submit comments. Comments may also 

be sent to the attention of Ms. Nickolette 

Roney, Division of Toxicology and 

Environmental Medicine, Agency for 

Toxic Substances and Disease Registry, 

Mailstop F–62, 1600 Clifton Road, NE., 

Atlanta, Georgia 30333, e-mail: 

tppubliccomment@cdc.gov. Send one 

copy of all comments and three copies 

of all supporting documents. Because all 

public comments regarding ATSDR 

toxicological profiles are available for 

public inspection, no confidential 

business information or other 

confidential information should be 

submitted in response to this notice. 

FOR FURTHER INFORMATION CONTACT: Ms. 

Delores Grant, Division of Toxicology 

and Environmental Medicine, Agency 

for Toxic Substances and Disease 

Registry, Mailstop F–62, 1600 Clifton 

Road, NE., Atlanta, Georgia 30333, 

telephone (770) 488–3351. 

SUPPLEMENTARY INFORMATION: The 

Superfund Amendments and 

Reauthorization Act (SARA) (Pub. L. 

99–499) amends the Comprehensive 

Environmental Response, 

Compensation, and Liability Act 

(CERCLA or Superfund) (42 U.S.C. 9601 

et seq.) by establishing certain 

responsibilities for ATSDR and the U.S. 

Environmental Protection Agency (U.S. 

EPA) with regard to hazardous 

substances most commonly found at 

facilities on the CERCLA National 

Priorities List (NPL). As part of these 

responsibilities, the ATSDR 

administrator must prepare 

toxicological profiles for substances 

enumerated on the priority list of 

hazardous substances. This list 

identifies 275 hazardous substances 

which, according to ATSDR and U.S. 

EPA, pose the most significant potential 

threat to human health. The availability 

of the revised priority list of 275 

hazardous substances was announced in 

the Federal Register on March 6, 2008 

(73 FR 12178). In addition, ATSDR has 

the authority to prepare toxicological 

profiles for substances not found at sites 

on the National Priorities List, in an 

effort to ‘‘* * * establish and maintain 

inventory of literature, research, and 

studies on the health effects of toxic 

substances’’ under CERCLA Section 

104(i)(1)(B), to respond to requests for 

consultation under section 104(i)(4), 

and as otherwise necessary to support 

the site-specific response actions 

conducted by ATSDR. 

Each profile will include an 

examination, a summary, and an 

interpretation of available toxicological 

information and epidemiological 

evaluations. This information and these 

data identify the levels of significant 

human exposure for the substance and 

for the associated health effects. The 

profiles must also include a 

determination of whether adequate 

information on the health effects of each 

substance is available or is in the 

process of development. If adequate 

information is not available, ATSDR, in 

cooperation with the National 

Toxicology Program (NTP), is required 

to ensure the initiation of research to 

determine such health effects. 

All toxicological profiles issued as 

‘‘Drafts for Public Comment’’ represent 

ATSDR’s best efforts to provide 

important toxicological information on 

priority hazardous substances. 

The draft toxicological profile will be 

made available to the public on or about 

April 29th, 2011. 

Hazardous substance CAS No. 

Uranium (Update) ..................... 7440–61–1 

Dated: April 21, 2011. 

Ken Rose, 

Director, Office of Policy, Planning and 

Evaluation, National Center for 

Environmental Health/Agency for Toxic 

Substances and Disease Registry. 

[FR Doc. 2011–10146 Filed 4–26–11; 8:45 am] 

BILLING CODE 4163–70–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60Day–11–11EQ] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. To 

request more information on the 

proposed projects or to obtain a copy of 

the data collection plans and 

instruments, call 404–639–5960 and 

send comments to Daniel Holcomb, CDC 

Reports Clearance Officer, 1600 Clifton 

Road, MS–D74, Atlanta, GA 30333 or 

send an e-mail to omb@cdc.gov. 

Comments are invited on: (a) Whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; 

(c) ways to enhance the quality, utility, 

and clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 

use of automated collection techniques 

or other forms of information 

technology. Written comments should 

be received within 60 days of this 

notice. 

Proposed Project 

Environmental Health Specialists 

Network (EHS-Net) National Voluntary 

Environmental Assessment Information 

System (NVEAIS)—New—National 

Center for Environmental Health 

(NCEH), Centers for Disease Control and 

Prevention (CDC). 

Background and Brief Description 

The CDC is requesting OMB approval 

for the EHS-Net National Voluntary 

Environmental Assessment Information 

System (NVEAIS) to collect data from 

foodborne illness outbreak 

environmental assessments routinely 

conducted by local, state, territorial, or 

tribal food safety programs during 

outbreak investigations. Environmental 

assessment data are not currently 

collected at the national level. The data 

reported through this information 

system will provide timely data on the 

causes of outbreaks, including 

environmental factors associated with 

outbreaks, and are essential to 

environmental public health regulators’ 

efforts to respond more effectively to 

outbreaks and prevent future, similar 

outbreaks. This information system is 

specifically designed to link to CDC’s 

existing disease outbreak surveillance 

system (National Outbreak Reporting 

System). 

The information system was 

developed by the Environmental Health 

Specialists Network (EHS-Net), a 

collaborative project of CDC, the U.S. 

Food and Drug Administration (FDA), 

the U.S. Department of Agriculture 

(USDA), and nine states (California, 

Connecticut, Georgia, Iowa, New York, 

Minnesota, Oregon, Rhode Island, and 

WReier-Aviles on DSKGBLS3C1PROD with NOTICES